SCHEMBL3150698

SCHEMBL3150698

CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2CC[Si](C)(C)CCC(=O)O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 18/20 0.78
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
ALDH1A1 P00352 3/20 0.61
GLA P06280 3/20 0.61
KDM4E B2RXH2 2/20 0.61
TP53 P04637 2/20 0.61
HPGD P15428 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
STAT6 P42226 1/20 0.61
CHEK1 O14757 1/20 0.61
HDAC3 O15379 1/20 0.61
ABCC4 O15439 1/20 0.61
GMNN O75496 1/20 0.61
LMNA P02545 1/20 0.61
CYP1A2 P05177 1/20 0.61
CYP3A4 P08684 1/20 0.61
HNRNPA1 P09651 1/20 0.61
GAA P10253 1/20 0.61
ALOX15 P16050 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13416188 1.00 TOP1 (0.78) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL3141567 0.93 TOP1 (0.73) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL13416186 0.93 TOP1 (0.73) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL3150912 0.92 TOP1 (0.81) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL3159585 0.91 TOP1 (0.80) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL3159674 0.91 TOP1 (0.80) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL3150335 0.91 TOP1 (0.80) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL3154899 0.91 TOP1 (0.80) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL3150122 0.91 TOP1 (0.66) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL13416185 0.91 TOP1 (0.66) TOP1MEN1KMT2AALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2197879-B1 C7-SUBSTITUTED CAMPTOTHECIN ANALOGS BIONUMERIK PHARMACEUTICALS INC (US) 2014-01-22 EP claimed
EP-2197879-A1 C7-SUBSTITUTED CAMPTOTHECIN ANALOGS BIONUMERIK PHARMACEUTICALS, INC. (US) 2010-06-23 EP claimed
US-7687496-B2 C7-substituted camptothecin analogs BIONUMERIK PHARMACEUTICALS, INC. (US) 2010-03-30 US claimed
WO-2009051580-A1 C7-SUBSTITUTED CAMPTOTHECIN ANALOGS BIONUMERIK PHARMACEUTICALS, INC. (US) 2009-04-23 WO claimed
US-20090099224-A1 C7- substituted camptothecin analogs BIONUMERIK PHARMACEUTICALS, INC. 2009-04-16 US claimed
EP-2197879-B1 C7-SUBSTITUTED CAMPTOTHECIN ANALOGS BIONUMERIK PHARMACEUTICALS INC (US) 2014-01-22 EP disclosed
US-7687496-B2 C7-substituted camptothecin analogs BIONUMERIK PHARMACEUTICALS, INC. (US) 2010-03-30 US disclosed
US-20090099224-A1 C7- substituted camptothecin analogs BIONUMERIK PHARMACEUTICALS, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099224-A1 C7- substituted camptothecin analogs ABCB1, ABCC1, ABCG2 TOP1 7/4885MEN1 2539/4885KMT2A 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.